

MANAGING DIRECTOR'S PRESENTATION – 2025 AGM

Adelaide, Australia, 17 November 2025: Leaders in AI microbiology automation, Clever Culture Systems Ltd (ASX: CC5) is pleased to provide the attached Managing Director's presentation, being provided at today's 2025 Annual General Meeting.

Approved for release by the CCS Board.

– ENDS –

About Clever Culture Systems

Clever Culture Systems (CCS) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading. The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

Clever Culture Systems
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@cleverculturesystems.com

ASX: CC5

*Revolutionising microbial quality
control in pharmaceutical
manufacturing*

Annual General Meeting

Brent Barnes, CEO and Managing Director
17 November 2025



**CLEVER CULTURE
SYSTEMS**



Clever Culture Systems

ASX: CC5

1



ersonal use only

Disclaimer

This document contains certain forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, we can give no assurance that these expectations will prove to be correct.

Given these uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors, risk and uncertainties including, without limitation, risks associated with estimating potential quantity and timing of sales, risks associated with medical device development and manufacture, risks inherent in the extensive regulatory approval processes mandated by regulatory authorities, delays in clinical trials, future capital needs, general economic uncertainty and other risks detailed from time to time in the Company's announcements to the ASX.

Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.

All reasonable efforts have been made to provide accurate information, but the Company does not undertake any obligation to release publicly any revisions to any "forward-looking statement" to reflect events or circumstances after the date of this presentation, except as may be required under applicable laws. Recipients should make their own enquiries in relation to any investment decisions from a licensed investment advisor.

NOT AN OFFER FOR SECURITIES

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.

UNITED STATES

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States.

OTHER JURISDICTIONS

This Presentation may only be accessed in other jurisdictions where it is legal to do so.



Blue-chip customers underpin FY25 profit - \$1.7m

Qualified leads ~\$75m upfront sales, \$15m recurring revenue*

Commercial

Industry leaders backing APAS® technology with global adoption - land and expand sales strategy

AstraZeneca, Bristol Myers Squibb, Pfizer, Novo Nordisk, Boehringer Ingelheim, Patheon (Thermo Fisher)

Corporate

FY25 maiden profit \$1.7m, driven by product sales of \$6.6m

High-margin growing recurring revenue ~\$1m

Sep-25 cash and current receivables of \$5.5 million

Outlook


New data presented by industry leaders – APAS® becoming the new standard environmental monitoring

Growing top-tier large pharma customers committing to APAS®

Commercial launch of contact plates expands APAS® utility for customers

*Sales estimate range is based on the potential number of APAS® instruments sold to current APAS users at an indicative average revenue per instrument sale of \$0.5 million (AUD) and recurring annual service and software fees of 20% of the instrument sales price. Assumes a USD:AUD exchange rate of 0.65. The amount is not risk weighted.

Millions of culture plates are manually read and reported annually during pharmaceutical manufacturing



Incorrect results costly

High cost of failure

Up to US\$1bn lost revenue¹

Failed results in pharmaceutical manufacturing can lead to substantial revenue losses. Catastrophic impact is patient death

Regulatory scrutiny

116% regulatory increase²

Rise in regulatory observations to drug establishments creates compliance challenges

Inefficient

Up to 98% zero growth plates³

Millions of plates reviewed annually, majority of plates have no growth yet require dual analyst verification, wasting resources

1. www.researchandmarkets.com, Global Pharmaceuticals Market Report 2021: Covid-19 Impact and Recovery to 2030.

2. <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations>

3. <https://www.cleverculturesystems.com/scientific-library/apas-pharmaqc-ai-culture-plate-reading>

Contact plates launch: unparalleled advantage

Launch Q1 FY26 to accelerate sales pipeline covering major tests

Settle Plates ~50% used

Contact Plates ~50% used



- Unlocks opportunity to convert and expand customer sales pipeline
- Current pipeline 40+ qualified leads built based on APAS automating ~50% workflow today, with knowledge of contact plate product pipeline being delivered
- Contact plate launch to automate majority of Environmental Monitoring tests



ersonal use only

Environmental monitoring delivered

Highest volume tests automated today


Validated analysis modules (AI software):

- Environmental monitoring: Settle Plates + Contact Plates




WebUI + transfer tool

APAS® IP: High precision AI software linked to imaging system



Opportunity to scale

- Imaging platform reused for different hardware configurations
- Existing analysis modules immediately compatible
- New analysis modules to automate more routine tests within pharmaceutical microbiology



Board and Management

Delivered expansion strategy into pharmaceutical manufacturing industry

- Board and Management shareholding 20%+
- International experience with healthcare, technology and pharmaceutical manufacturing expertise
- Extensive public listed ASX experience in micro-cap and high-growth companies



Brent Barnes
CEO and MD, AU
Aug-16 start



Rebecca Wilson
Chair, AU
Jul-23 start



Dan Hill
NED, AU
Dec-23 start



Ian Wisenberg
NED, US
Oct-24 start



Ray Ridge
CFO and
CoSec, AU

APAS INDEPENDENCE



New sales and placements with Top-20 pharma companies

Sets established userbase for future sales

Growth in customers using the technology in routine operations

Drives growth in recurring revenues

Contact plate application provides unique value proposition for customers

Expands overall APAS market opportunity

Increased customer support for APAS:

User groups, customer presentations, validation approach to support adoption